“…Consistent with roles in diverse, important cellular processes, disrupted ESCRT function through knockout of ESCRT-0 (hrs) [9], ESCRT-I (tsg101) [10], ESCRT-III (chmp5) [11] or the ESCRT-associated factor HD-PTP (ptpn23) [12] result in embryonic lethality in mouse models. Moreover, mutations altering ESCRT function have been linked to congenital disorders including spastic paraplegia (SP80, UBAP1; SP53, Vps37A) [13][14][15], childhood cataracts (CTRCT31, CHMP4B) [16,17], frontotemporal dementia (FTD/ALS17, CHMP2B) [18][19][20][21], pontocerebellar hypoplasia (PCH8, CHMP1A) [22], cerebellar hypoplasia, cataracts, impaired intellectual development, congenital microcephaly, dystonia, dyserythropoietic anemia, and growth retardation (CIMDAG, VPS4A) [23][24][25] and neurodevelopmental disorder with structural brain anomalies, seizures and spasticity (NEDBASS, HDPTP/PTPN23) [26][27][28][29][30] (also reviewed in [31]). While the ESCRTs serve important roles facilitating development and maintaining organismal homeostasis, the lack of a viable ESCRT-deficient mouse model has precluded a deeper understanding of how this is achieved.…”